The Stokoe lab uses cancer genomics, combined with phenotypic screening, to identify and validate novel oncology drug targets.
Following his postdoc at Onyx Pharmaceuticals, David moved to the University of California at San Francisco to start a lab working on signaling pathways deregulated in cancer. He then joined Genentech to apply some of these findings in a translational setting, and to pursue target identification through cancer genomics and analysis of epigenetic alterations.
- Postdoc, Onyx Pharmaceuticals
- Ph.D. in Biochemistry, University of Dundee
- B.Sc. in Biochemistry, University of Bristol